TY - JOUR T1 - Outcome variables for osteoarthritis clinical trials: The OMERACT-OARSI set of responder criteria. JF - The Journal of Rheumatology JO - J Rheumatol SP - 1648 LP - 1654 VL - 30 IS - 7 AU - Thao Pham AU - Désirée Van Der Heijde AU - Marissa Lassere AU - Roy D Altman AU - Jennifer J Anderson AU - Nicholas Bellamy AU - Marc Hochberg AU - Lee Simon AU - Vibeke Strand AU - Thasia Woodworth AU - Maxime Dougados AU - OMERACT-OARSI Y1 - 2003/07/01 UR - http://www.jrheum.org/content/30/7/1648.abstract N2 - Improvement in analysis and reporting results of osteoarthritis (OA) clinical trials has been recently obtained because of harmonization and standardization of the selection of outcome variables (OMERACT 3 and OARSI). Moreover, OARSI has recently proposed the OARSI responder criteria.This composite index permits presentation of results of symptom modifying clinical trials in OA based on individual patient responses (responder yes/no). The 2 organizations (OMERACT and OARSI) established a task force aimed at evaluating: (1) the variability of observed placebo and active treatment effects using the OARSI responder criteria; and (2) the possibility of proposing a simplified set of criteria. The conclusions of the task force were presented and discussed during the OMERACT 6 conference, where a simplified set of responder criteria (OMERACT-OARSI set of criteria) was proposed. ER -